Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (NYSE:PFE) from Buy to Neutral. Analyst Price Forecast Suggests 39.12% Upside As of April 1, 2025 ...

Goldman Sachs downgraded Pfizer (PFE) to Neutral from Buy with a price target of $25, down from $32, after assuming coverage of the name. The firm says that on the back of a challenging past two ...

In today’s CEO Daily: Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political ...

BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV). Eli Lilly (LLY) has ended a three-day selloff after Goldman Sachs analyst Asad Haider upgraded the Indiana-based drugmaker to Buy from Neutral ...

On this episode of Stock Movers: - Goldman Sachs (GS) shares are higher after ... maintaining her $225 price target. - Pfizer (PFE) is down today as it plans to abandon its obesity pill ...

Pharmaceutical giant Pfizer (PFE) has been through a rough spot in 2025, joining the rest of the stock market as President Donald Trump’s trade ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (SNSE:PFE) from Buy to Neutral. There are 4,005 funds or institutions reporting positions in Pfizer.

Fintel reports that on April 8, 2025, Goldman Sachs downgraded their outlook for Pfizer (SNSE:PFECL) from Buy to Neutral. There are 4,005 funds or institutions reporting positions in Pfizer.

Goldman Sachs (GS) shares rise after stock traders ... according to a statement Monday. - Pfizer (PFE) shares edge lower after it halted development of its highest profile experimental drug ...